Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01184885
Recruitment Status : Completed
First Posted : August 19, 2010
Results First Posted : January 3, 2014
Last Update Posted : December 18, 2017
Sponsor:
Collaborator:
American Society of Clinical Oncology
Information provided by (Responsible Party):
Thomas Jefferson University ( Sidney Kimmel Cancer Center at Thomas Jefferson University )

Tracking Information
First Submitted Date  ICMJE August 17, 2010
First Posted Date  ICMJE August 19, 2010
Results First Submitted Date  ICMJE November 13, 2013
Results First Posted Date  ICMJE January 3, 2014
Last Update Posted Date December 18, 2017
Study Start Date  ICMJE July 2010
Actual Primary Completion Date March 2011   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: April 16, 2014)
Number of Participants With Count Recovery That Allows for Starting a Phase II Study to Evaluate Response Rates and Survival [ Time Frame: 18 months ]
This will be assessed by evaluating the tolerability of this regimen compared to historical controls who received Hyper-CVAD or Hyper-CVAD/ Rituximab regimens. The treatment will be designated feasible for an individual subject if in 80% of chemotherapy cycles the subject has count recovery that allows for starting the subsequent cycle by Day 28. Count recovery is defined as ANC (absolute neutrophil count) of > 0.5 x 10^9/L and platelet count > 50 x 10^9/L. Hyper-CVAD/Rapamycin will be deemed acceptable if it is feasible to administer in 80% or more of subjects.
Original Primary Outcome Measures  ICMJE
 (submitted: August 17, 2010)
To determine the feasibility of therapy with Hyper-CVAD and Rapamycin in adults with Acute Lymphoblastic Leukemia (ALL) and other aggressive lymphoid malignancies. [ Time Frame: 18 months ]
This will be assessed by evaluating the tolerability of this regimen compared to historical controls who received Hyper-CVAD or Hyper-CVAD/ Rituximab regimens. The treatment will be designated feasible for an individual subject if in 80% of chemotherapy cycles the subject has count recovery that allows for starting the subsequent cycle by Day 28. Count recovery is defined as ANC of > 0.5 x 109 AND Platelet count > 50 x 109/L. Hyper-CVAD/Rapamycin will be deemed acceptable if it is feasible to administer in 80% or more of subjects.
Change History Complete list of historical versions of study NCT01184885 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: April 16, 2014)
  • Induction Mortality [ Time Frame: 18 months ]
    Induction mortality. Hyper-CVAD/ Rapamycin will be considered acceptable if induction mortality does not exceed 31% in patients older than 60, or 15% in those younger than 60
  • Complete Response [ Time Frame: Every 21 days or as count recovery allows (at least 14 days apart) up to 24 weeks ]
    To describe response rates to hyper-CVAD and sirolimus in adults with ALL and other aggressive lymphoid malignancies. Bone marrow (<5% blasts) with adequate bone marrow cellularity, no evidence of circulating blasts or extramedullary disease and normalization of peripheral blood counts except for platelets (neutrophil count =1,000/µL).
Original Secondary Outcome Measures  ICMJE
 (submitted: August 17, 2010)
Induction Mortality [ Time Frame: 18 months ]
Induction mortality. Hyper-CVAD/ Rapamycin will be considered acceptable if induction mortality does not exceed 31% in patients older than 60, or 15% in those younger than 60
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy
Official Title  ICMJE A Pilot Study of Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone (Hyper-CVAD) With Sirolimus for the Treatment of Adult Acute Lymphoblastic Leukemia and Aggressive Lymphoid Malignancies
Brief Summary This is a pilot study, assessing the feasibility, safety and toxicity of an mTOR (mammalian target of Rapamycin) inhibitor (MTI), rapamycin, when administered with HyperCVAD (Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicine and Dexamethasone), with an ultimate goal to perform a phase II study to evaluate response rates and survival in adults with Acute Lymphoblastic Leukemia (ALL) and aggressive lymphoid malignancies.
Detailed Description

The primary objective of this trial is to characterize the feasibility, safety and tolerability of therapy with Hyper-CVAD and Rapamycin in adults with ALL and other aggressive lymphoid malignancies.

This study will evaluate the effectiveness of Rapamycin given in combination with Hyper-CVAD during A treatment cycles, and Methotrexate and Cytarabine in B treatment cycles. Both cycles will also contain the drug Rituximab if the patient has a B cell type of leukemia or lymphoma.

This combination of drugs are being studied to determine whether or not these drugs will have an effect in treating this disease.

Current therapeutic regimens for induction of remission in ALL are broadly similar. There is no single best regimen for induction therapy. The hyper-CVAD regimen is of particular interest because it does not include asparaginase as part of the therapeutic regimen and the results of induction are similar to other published regimens.

The HyperCVAD regimen with or without rituximab is also an accepted induction regimen for lymphoblastic lymphoma, Burkitt and Burkitt like lymphoma, Mantle Cell Lymphoma, and ALL in the elderly. The regimen has also been used as a salvage regimen in patients with the above diagnoses who have relapsed after another induction regimen.

This trial will add a novel agent, an mTOR inhibitor (MTI), rapamycin, to act synergistically with the HyperCVAD regimen. This is a pilot study, assessing the feasibility, safety and toxicity of this regimen, with an ultimate goal to perform a phase II study to evaluate response rates and survival.

This is a pilot study of the Hyper-CVAD regimen with Rapamycin for the treatment of adults with acute lymphoblastic leukemia or other aggressive lymphoid malignancies. The standard Hyper-CVAD regimen will be used, with the addition of the investigational agent, Rapamycin. Hyper-CVAD alone is one of the current standard induction and salvage regimens used to treat ALL and other aggressive lymphoid malignancies.

Subjects included will have either de novo, relapsed, or refractory ALL or another aggressive lymphoid malignancy.

Chemotherapy will consist of 4 'A' cycles alternating with 4 'B' cycles, every 21 days, or as count recovery allows (at least 14 days apart) as follows: 1A; 1B; 2A; 2B, 3A; 3B; 4A; 4B. This is dependent on white blood cell count recovery.

Study Type  ICMJE Interventional
Study Phase  ICMJE Early Phase 1
Study Design  ICMJE Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Lymphoid Malignancies (New or Relapsed)
  • Acute Lymphoblastic Leukemia
  • Burkitt Lymphoma
  • Lymphoblastic Lymphoma
  • Mantle Cell Lymphoma
  • Adult T-cell Leukemia/Lymphoma
Intervention  ICMJE
  • Drug: Hyper-CVAD
    • Cycle A: Cyclophosphamide 300mg/m2 every 12 hours on days 3-5; Vincristine 2mg/day on days 6 and 13; Doxorubicin 50mg/m2 on day 6; Decadron 40mg/ day po on days 3-6 and 13-16; Methotrexate 12mg IT on day 4; Ara-C 100mg IT on day 9.
    • Cycle B: Methotrexate 1000mg/m2 on day 3; Leucovorin 50mg every 6 hours starting 24 hours from the beginning of the MTX infusion until MTX levels are < 0.1 umol/L; Ara-C 3000mg/m2 every 12 hours on days 4 and 5; Methotrexate 12mg IT on day 4; Ara-C 100mg IT on day 9.
    • Rituximab (if given) will be 375 mg/m2 on Days 3 and 13 of Cycle A and on Days 4 and 9 of cycle B, for a total of 8 doses over the first 4 courses.
    Other Names:
    • Cytoxan
    • Endoxan
    • Neosar
    • Procytox
    • Revimmune
    • Cytophosphane
    • Oncovin
    • Leurocristine
    • Adriamycin
    • Hydroxydaunorubicin
    • MTX
    • Amethopterin
  • Drug: Sirolimus
    Sirolimus loading dose of 12mg on day 1 followed by a single daily dose of 4 mg/ day on days 2 through 7 (Cycle A) and on days 2 through 6 (Cycle B)
    Other Name: Rapamycin
Study Arms  ICMJE Experimental: Hyper-CVAD and Sirolimus
Hyper-CVAD and Sirolimus
Interventions:
  • Drug: Hyper-CVAD
  • Drug: Sirolimus
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: January 6, 2012)
7
Original Estimated Enrollment  ICMJE
 (submitted: August 17, 2010)
12
Actual Study Completion Date  ICMJE April 2013
Actual Primary Completion Date March 2011   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Patients must have a diagnosis of one of the following lymphoid malignancies (new or relapsed):

    • Acute Lymphoblastic Leukemia (B and T cell, Philadelphia Chromosome Negative)
    • Burkitt Lymphoma
    • Burkitt - type Lymphoma
    • Lymphoblastic Lymphoma
    • Mantle Cell Lymphoma
    • Adult T cell Leukemia/ lymphoma
  2. Patients must be >18 years old
  3. Patients must have an ECOG performance status of 0 or 1(see attachment 1).
  4. Patients must have a life expectancy of at least 4 weeks.
  5. Patients must be able to consume oral medication.
  6. Patients must have completed any radiotherapy four weeks prior to study entry, 0-2 weeks for local palliative XRT (small port).
  7. Patients must have recovered from the toxic effects of any prior chemotherapy to < grade 2 (except alopecia).
  8. Required initial laboratory values: Creatinine < or = 2.0mg/dL; total or direct bilirubin < or = 1.5mg/dL (if not due to the leukemia or lymphoma itself); SGPT(ALT) < or = 3xULN; glucose <200 mg/dL, negative pregnancy test for women with child-bearing potential.
  9. Patients must be able to sign consent and be willing and able to comply with scheduled visits, treatment plan and laboratory testing.
  10. Patients may have had a prior stem cell transplant (autologous or allogeneic), however they may not have active GvHD, nor be on any immunosuppression

Exclusion Criteria:

  1. Patients must not be receiving any chemotherapy agents (except Hydroxyurea)
  2. Intrathecal ARA-C and intrathecal methotrexate are permissible (as they are not systemic and only isolated to the central nervous system).
  3. Patients must not be receiving growth factors, except for erythropoietin.
  4. Patients with a current second malignancy requiring systemic therapy, other than non-melanoma skin cancers, are not eligible.
  5. Patients with uncontrolled high blood pressure, unstable angina, symptomatic congestive heart failure, myocardial infarction within the past 6 months or serious uncontrolled cardiac arrhythmia are not eligible.
  6. Patients taking any of the following drugs while on-study are not eligible:

    1. Carbamazepine (e.g. Tegretol)
    2. Rifabutin (e.g. Mycobutin)
    3. Rifampin (e.g. Rifadin)
    4. Rifapentine (e.g. Priftin)
    5. St. John's Wort- may decrease the effects of sirolimus by decreasing the amount of sirolimus in the body
    6. Clarithromycin (e.g. Biaxin)
    7. Cyclosporin e.g. (Neorla or Sandimmune)
    8. Diltiazem (e.g. Cardizem)
    9. Erythromycin (e.g. Akne-Mycin, Ery-Tab)
    10. Itraconazole (e.g. Sporanox)
    11. Ketoconazole (e.g. Nizoral)
    12. Telithromycin (e.g. Ketek)
    13. Verapamil (e.g. Calan SR, Isoptin, Verelan)
    14. Voriconazole (e.g. VFEND) - May increase the effects of sirolimus by increasing the amount of this medicine in the body. [Cannot be taken within 72 hours prior to or subsequent to receiving rapamycin, but may be taken prior to or after the above time period]
    15. Tacrolimus (e.g. Prograf) - May cause liver transplant rejection or serious side effects in patients on sirolimus.
  7. Patients with known HIV positivity or AIDS-related illness are not eligible.
  8. Patients with other severe concurrent disease which in the judgment of the investigator would make the patient inappropriate for entry into this study are ineligible.
  9. Patients must not have evidence of cerebellar dysfunction or prior history of cerebellar dysfunction with Ara-C administration.
  10. Patients must not have received any investigational agents within 30 days of study entry.
  11. Patients must not be pregnant or breastfeeding. Pregnancy tests must be obtained for all females of child-bearing potential. Pregnant or lactating patients are ineligible for this study due to the unknown human fetal or teratogenic toxicities of rapamycin. Males or females of reproductive age may not participate unless they have agreed to use an effective contraceptive method.
  12. Patients who have uncontrolled infection are not eligible. Patients must have any active infections under control. Fungal disease must be stable for at least 2 weeks before study entry. Patients with bacteremia must have documented negative blood cultures prior to study entry.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01184885
Other Study ID Numbers  ICMJE 09G.474
2009-35 ( Other Identifier: CCRRC )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Thomas Jefferson University ( Sidney Kimmel Cancer Center at Thomas Jefferson University )
Study Sponsor  ICMJE Sidney Kimmel Cancer Center at Thomas Jefferson University
Collaborators  ICMJE American Society of Clinical Oncology
Investigators  ICMJE
Principal Investigator: Margaret Kasner, MD Thomas Jefferson University
PRS Account Thomas Jefferson University
Verification Date November 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP